OrthoPediatrics (NASDAQ:KIDS) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of OrthoPediatrics (NASDAQ:KIDS) from a hold rating to a sell rating in a research note released on Saturday morning.

A number of other analysts have also recently commented on KIDS. Citigroup reiterated an “outperform” rating on shares of OrthoPediatrics in a research note on Friday, October 10th. Truist Financial set a $18.00 price objective on shares of OrthoPediatrics in a research note on Friday, October 10th. Piper Sandler cut their target price on OrthoPediatrics from $30.00 to $22.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. BTIG Research reaffirmed a “buy” rating and set a $23.00 price target on shares of OrthoPediatrics in a research report on Wednesday, October 29th. Finally, JMP Securities dropped their price target on OrthoPediatrics from $35.00 to $25.00 and set a “market outperform” rating on the stock in a research note on Friday, October 10th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

OrthoPediatrics Stock Up 1.7%

OrthoPediatrics stock opened at $17.36 on Friday. OrthoPediatrics has a 1-year low of $15.28 and a 1-year high of $27.60. The business has a fifty day moving average price of $17.45 and a 200-day moving average price of $19.41. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.40 and a quick ratio of 3.52. The stock has a market capitalization of $435.39 million, a price-to-earnings ratio of -8.90 and a beta of 1.06.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Monday, January 9th. The company reported ($0.15) earnings per share (EPS) for the quarter. The business had revenue of $25.08 million for the quarter. OrthoPediatrics had a negative net margin of 20.06% and a negative return on equity of 6.86%. Equities research analysts forecast that OrthoPediatrics will post -0.93 EPS for the current fiscal year.

Institutional Trading of OrthoPediatrics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Prosight Management LP lifted its holdings in OrthoPediatrics by 319.2% in the third quarter. Prosight Management LP now owns 308,707 shares of the company’s stock valued at $5,720,000 after acquiring an additional 235,060 shares during the period. Millennium Management LLC increased its holdings in shares of OrthoPediatrics by 55.3% during the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock valued at $16,172,000 after purchasing an additional 233,873 shares in the last quarter. Harbor Capital Advisors Inc. lifted its stake in shares of OrthoPediatrics by 116.5% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 333,959 shares of the company’s stock valued at $7,173,000 after purchasing an additional 179,733 shares during the period. Deerfield Management Company L.P. boosted its holdings in OrthoPediatrics by 1,153.4% during the third quarter. Deerfield Management Company L.P. now owns 194,109 shares of the company’s stock worth $3,597,000 after buying an additional 178,623 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY boosted its holdings in OrthoPediatrics by 1,607.0% during the first quarter. Paradigm Capital Management Inc. NY now owns 170,700 shares of the company’s stock worth $4,204,000 after buying an additional 160,700 shares in the last quarter. 69.05% of the stock is owned by institutional investors and hedge funds.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.